ESTRO Brachytherapy for Prostate Cancer 2018

Disease progression free survival dependent on PSA level, preoperativ parameter

< 4ng/ml → 5 years progression free probabiity 86%

Cancer survival < 10ng/ml vs >10ng/ml → 10 years

vs.55%

vs.28%

Bianco FJ IJROBP 2005